Table 1.
Reference | Characteristics | ORR, % | mPFS, months | mOS, months since start of ICI |
---|---|---|---|---|
Mazieres J., et al. (31) | ALK (n=23) | 0 | 2.5 | 17 |
Gainor JF.,et al. (32) | ALK (n=6) | 0 | ||
Jahanzeb M., et al. (33) | ALK (n=83) | 2.34 | ||
Gadgeel SM. et al. (34) | ALK (n=7) | 28.6% | 2.9 | 2.9 |
ICIs, immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; ORR, overall response rate; mPFS-median progression-free survival; mOS, median overall survival.